Flagship's Generate:Biomedicines files for IPO, pitching AI-driven drugs
Flagship旗下的Generate:Biomedicines提交IPO文件，主打AI驱动药物

Just nine days after dosing the first patient in a Phase 3 trial, Generate:Biomedicines has filed for an IPO.
在启动三期试验并为首位患者给药后的第九天，Generate:Biomedicines便提交了IPO申请。